Market Intelligence, Clinical Progress, and High-Purity Reagents for Retinitis Pigmentosa and Spliceosome-Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRPF8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRPF8 Recombinant Protein (Jab1/MPN Domain WT / Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View PRPF8 Products |
| Gene Delivery | PRPF8 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View PRPF8 Products |
| Benchmark Ab | Anti-PRPF8 Recombinant Antibody Recombinant positive control for IP/WB and localization assays. |
View PRPF8 Products |
| Validator | PRPF8 siRNA Set For knockdown verification and functional assay validation. |
View PRPF8 Products |
| Related Target A | SF3B1 Core spliceosome component; synergistic target in myeloid leukemia and solid tumors. |
View SF3B1 Products |
| Related Target B | SRSF2 Splicing factor frequently co-mutated or targeted in RNA-splicing oncology pathways. |
View SRSF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large molecular weight (~270 kDa) expression limitations | Truncated, functionally active domains (e.g., Jab1/MPN) expressed in insect cells with verified purity (>95%) |
| RP13-associated mutant screening | Sequence-verified mutant proteins (H2309P, F2314L) available for differential binding assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PRPF8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRPF8 therapeutics is intensifying, with major players shifting focus from traditional gene replacement to spliceosome modulation and targeted protein-protein interaction (PPI) inhibitors. As first-generation gene therapies for Retinitis Pigmentosa 13 (RP13) reach preclinical and early clinical milestones, the next wave of R&D is targeting PRPF8-dependent splicing vulnerabilities in MYC-driven and spliceosome-mutated cancers (such as MDS and AML).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / ASO | Academic Medical Centers, Ocular Biotech | Retinitis Pigmentosa 13 (RP13) | Functional rescue assays (Need lentiviruses expressing WT vs Mutant PRPF8) |
| Small Molecule (PPI Inhibitors) | Oncology-focused Biopharma | MDS, AML, Solid Tumors | In vitro binding/displacement assays (Need high-purity recombinant Jab1/MPN domains) |
| RNAi / Knockdown | RNA Therapeutics Specialists | Splicing-addicted Cancers | Target validation and knockdown efficiency controls (Need sequence-verified siRNA) |